Update Note: This article reports new information involving the Department of Health and Human Services' Sept. 21, 2026, package of animal-testing actions following MedicalDaily's earlier coverage of the FDA rule. The newest details come from NIH, HHS, and FDA announcements dated Sept. 21, 2026.
The National Institutes of Health is spending $88 million on 10 construction projects in nine states to build facilities for research methods based on human biology rather than animals. It is also asking research institutions whether it should publish a yearly public count of the live vertebrate animals used in NIH-funded labs, according to an NIH announcement.
The moves were part of a broader HHS package released the same day the FDA issued a rule clarifying that non-animal safety data can be used where appropriate. They shift the story from regulatory language to something taxpayers can track: money and public accountability.
For patients, the stakes are long-term. Many drugs that look promising in early testing, including animal studies, fail once they reach human trials. Better human-based tools could, in theory, weed out failures earlier. Whether they will is not yet proven.
Where the Research Dollars Are Headed
The $88 million comes through NIH's Biomedical Research Facilities Program. NIH said many past awards in that program supported buildings focused on animal models. The new projects target chronic disease, environmental health, rare childhood diseases, cancer, and obesity. Several go to Institutional Development Award states, where NIH aims to build research capacity in places that lag peer states and where those gaps may affect local health.
NIH also launched a challenge offering more than $7 million in prizes for quantum-based sensors that improve measurements in lab tools such as organ-on-a-chip devices. It plans an automated human biology laboratory at the NIH Clinical Center that combines standardized organoids, robotics, and artificial intelligence. The agency is also recruiting grant reviewers with expertise in human-based science.
"NIH is building the scientific infrastructure needed to develop, validate, and scale technologies that better reflect human biology," said NIH Director Jay Bhattacharya. Nicole Kleinstreuer, NIH deputy director for program coordination, planning, and strategic initiatives, said the awards "will help build that foundation by expanding access to resources, expertise, and infrastructure."
The announcement did not name the individual awardees or break down funding by state, details that would help the public judge where the money is going.
A Possible Public Count and Parallel Agency Moves
The transparency piece is a request for information, not a commitment. In a notice to NIH-funded institutions, NIH's Office of Laboratory Animal Welfare is asking about the feasibility, benefits, and burdens of reporting yearly animal numbers. NIH said such reporting would increase transparency and help measure progress on reducing animal use.
Other agencies announced their own steps. The CDC said it is substantially reducing its laboratory animal colony and working to permanently place healthy nonhuman primates in a sanctuary. "We are applying greater scrutiny to animal research and focusing our resources on science that directly advances our public health mission," said CDC Director Erica Schwartz.
HHS said FDA guidance changes are expected to spare hundreds of nonhuman primates and more than one million horseshoe crabs each year. The crabs' blood has long been used to test medicines for bacterial contamination. The Advanced Research Projects Agency for Health is funding computer models to predict drug safety and dosing.
"By removing outdated barriers to new approach methodologies, we can reduce unnecessary animal testing while making product development more predictive and efficient," said Acting FDA Commissioner Kyle Diamantas. HHS has posted a running list of more than 20 actions taken so far.
Promise, Proof, and the Questions Still Open
The FDA's direct final rule replaces terms such as "animal studies" with "nonclinical studies" in its regulations. The FDA said the rule does not eliminate or prohibit animal studies, change evidence standards, or impose new requirements on drug developers. If the agency receives significant adverse comments, it will withdraw the rule and continue through standard rulemaking, according to the Federal Register notice.
What is new is the scale of spending and the prospect of public animal counts. Those steps could make the policy measurable. They do not show that any single alternative method predicts human safety better than animal studies. NIH itself said animal models are "still an important tool," and every new method must be validated for its specific use. Because the facilities and challenge were only just announced, no independent evaluation of their results exists yet.
Nothing changes immediately at the pharmacy counter. Medicines on the market today were tested under existing rules, and people joining clinical trials keep the same safety protections. Patients with cancer and rare diseases, who often wait longest for new treatments, stand to gain most if validated methods speed early testing, though that benefit has not been measured. Anyone considering a trial can ask the study team what safety testing came before the first human doses.
The public can comment on the FDA rule through the Federal Register, and researchers and institutions can respond to the NIH request for information.
The newest development is money and measurement. NIH is funding facilities for human-based research and weighing a public tally of lab animals. The practical effect on medicines will take years to judge, and the central uncertainty is whether these tools prove reliable enough to replace animal studies at scale.
Key Questions Answered
What did NIH announce? $88 million for 10 construction projects in nine states to support human-based research methods, plus a challenge offering more than $7 million in prizes, a new Clinical Center lab, and a reviewer recruitment effort.
Will NIH publish how many animals it uses? Not yet. NIH is asking institutions whether a yearly public count of live vertebrate animals in NIH-funded labs is feasible.
Does this end animal testing? No. The FDA rule allows validated non-animal methods where appropriate, and NIH says animal models remain an important tool.
What is the CDC doing? The CDC says it is substantially reducing its lab animal colony and working to place healthy nonhuman primates in a sanctuary.
Does this affect my medicines now? No. Drugs on the market and people in clinical trials remain under existing safety standards.
Can the FDA rule still change? Yes. If the FDA receives significant adverse comments, it will withdraw the direct final rule and proceed through standard rulemaking.
How can the public weigh in? Comments on the FDA rule can be filed through the Federal Register, and institutions can respond to NIH's request for information.
Published by Medicaldaily.com
